Clinical trial
Ended Definitive Contract Awarded Last action
- Contract number
- W81XWH18C0074
- Awardee
-
Amplyx Pharmaceuticals, Inc. UEI N4A8X52DCND5 Part of Pfizer Inc.
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $2,734,526
Award facts
- Opportunity
-
- W81XWH17RBAA1 Solicitation number
- FY17 USAMRMC Broad Agency Announcement Award Notice · Posted Sep 30, 2016
- Contract value 100% obligated
- $2,734,526.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Alternative Sources
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92130, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$754,368 | |
| Change Order | $0 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Original award | $3,488,894 |
About this award
This is a firm-fixed-price contract awarded by the Department of the Army Medical Command to Amplyx Pharmaceuticals, Inc., a subsidiary of Pfizer Inc., to conduct a clinical trial. The contract has a potential value of $2,734,526.00 and a completion date of December 5, 2021. The contract does not have a set-aside designation. As a large pharmaceutical company, Pfizer has a history of providing various pharmaceutical products and services to U.S. government agencies through federal contract awards, including COVID-19 vaccines, intravenous solutions, injections, vaccines, and other medical products. Pfizer also holds a Blanket Purchase Agreement against the Pharmaceuticals and Drugs GSA Schedule to supply Oxybryta to treat sickle cell disease, and multiple indefinite-delivery, indefinite-quantity contracts to provide various adult vaccines to support immunization programs administered by the CDC and state health departments.
Quick answers
Who was awarded contract W81XWH18C0074?
W81XWH18C0074 was awarded to Amplyx Pharmaceuticals, Inc. by Medical Command (Department of the Army) on March 6, 2018.
How much is contract W81XWH18C0074 worth?
The government has obligated $2,734,526 on W81XWH18C0074.
Was contract W81XWH18C0074 competed?
The extent of competition for W81XWH18C0074 was full and open competition after exclusion of sources. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award